GlycomineBio
About GlycomineBio
GlycomineBio is a biotechnology startup focused on developing replacement therapies for rare genetic diseases, specifically advancing GLM-101 into a phase IIb study in patients with PMM2CDG, a congenital disorder of glycosylation.
Business Information
Traction
Key Metric
Secured $115 million in Series C financing to support clinical trials
Location
San Carlos , California , USA North America
Target Customers
Industry Categories
Business Model
Funding Timeline
| Round | Date | Amount | Investors |
|---|---|---|---|
| Series C | Apr 17, 2025 | $115.0M | Unknown |
Founders
No founder information available.
Investors
No investor information available.
Recent Mentions
“It’s a challenging environment to raise money,” said Steve Axon, CEO of @GlycomineBio, which nevertheless secured $115 million in a series C #financing round to support the advancement of GLM-101 into a phase IIb study in patients with #PMM2CDG https://t.co/Mkldi8N3WO #biopharma
Similar Startups
No similar startups found.
Other Data Sources
2Exa Startup Data
Apr 21, 2025Twitter Startup Data
Apr 20, 2025Exa Enrichment History
1Fields Updated
Enrichment Details
- Description
- GlycomineBio is a biotechnology startup focused on developing replacement therapies for rare genetic diseases, specifically advancing GLM-101 into a phase IIb study in patients with PMM2CDG, a congenital disorder of glycosylation.
- Website
- https://www.glycomine.com/
- Industry
- Biotechnology, Pharmaceuticals, Healthcare
- Enrichment History
-
- {'updated_at': '2025-04-24T18:44:16.694872', 'fields_updated': {'description': True, 'industry': True, 'website': True}, 'query_used': 'GlycomineBio website:https://www.glycomine.com/ Biotechnology, Pharmaceuticals, Healthcare company business model funding', 'sources_count': 5}